Uncategorized

ASCENSIA DIABETES CARE PRESENTS NEW RESEARCH SHOWING THAT PEOPLE USING THE CONTOUR® BLOOD GLUCOSE MONITORING SYSTEM AND APP EXPERIENCE FEWER OUT-OF-TARGET BLOOD GLUCOSE LEVELS

Basel, Switzerland, May 2, 2022 /PRNewswire/ — Ascensia Diabetes Care, a global diabetes care company, maker of CONTOUR® Portfolio of blood glucose monitoring systems (BGM) and distributor of Eversense® continuous glucose monitoring (CGM) system announces a new study showing that people who use the connected CONTOUR® BGM systems (BGMS) and CONTOUR®DIABETES App (CDA) for at least six months can see a reduced frequency of hypoglycemic and hyperglycemic blood glucose readings (BGRs). BGRs in these off-target areas can lead to serious health complications, indicating a key benefit of using Ascensia’s connected CONTOUR® BGMS and CDA together (the CDA system). Real-world data from this study was presented at the 2022 International Conference on Advanced Technologies & Treatments for Diabetes (ATTD).

The study, which included data from 7,047 users of the CDA system in Australia, showed a reduction in BGR frequency in both the hypoglycemic (low) and hyperglycemic (high) ranges. At six months, the estimated frequency of high and very high range BGRs in subjects using the CDA system decreased by more than 6.5-fold and 5.6-fold, respectively, from baseline. This decrease was more pronounced in users who reported taking oral antidiabetics, with a 7.37-fold decrease from baseline. The decrease in low-range BGRs was moderate at 1.2-fold in the entire population studied and at 1.38-fold in CDA System users who were insulin-treated and more susceptible to hypoglycemic events. These data indicate improved glycemic control when the CDA system is used for at least six months and, more generally, a significant benefit in using connected BGMS, including apps, to support diabetes management.

The majority of CDA System users in the group evaluated were people with type 2 diabetes (66.9%), for whom improvement in glycemic control is associated with reduced progression of diabetes-related complications[1]. As diabetes apps continue to permeate clinical care, these results offer the potential to investigate how a connected BGMS with visibility and accessibility of blood glucose readings can support self-management for people with type 1 and type 2 diabetes.

Frank HeldHead of BGM Marketing and Strategy at Ascensia Diabetes Care, said: “We are pleased with the results of the study, which show that our CDA system helps people with diabetes manage their condition, they do not provide any warnings or guidance for hypoglycemic.” or hyperglycemic events, such as the CONTOUR®DIABETES app does. If these events are not properly managed, they can lead to serious health complications, so it is vital that monitoring systems and connected apps make it easier to detect high and low blood glucose levels.”

Prior to this study, there was limited data evaluating the impact of diabetes apps in Australia, especially in a “real world” environment. Although evidence suggests that there are hundreds of diabetes apps out there to help people with diabetes manage their blood sugar, only a third of these apps have warnings or guidance for hypoglycemic and/or hyperglycemic events[2]. If left untreated, these events can become serious and lead to serious complications[3]therefore, it is paramount that monitoring tools help people with diabetes manage these events.

The poster of this study, entitled “Assessment of Blood Glucose Readings of People with Diabetes in Australia who used the connected CONTOUR®BGMS and CONTOUR®DIABETES App” was presented from a study led by Wendy Mak PhD, Scott Pardo PhD, PStat®and Rimma Shaginian, MD, MPH. ATTD 2022 took place in Barcelona, ​​Spain out of 27-30 April 2022.

1. Stratton, IM, et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPD 35); Prospective observational study. BMW 2000; 321:205-412.
2. Lum E, Jimenez G, Huang Z et al (2019) Decision support and alerts from blood glucose self-monitoring apps in type 2 diabetes. JAMA 321(15):1530 1530-1532. https://doi.org/10.1001/jama.2019.1644.
3. Mayo Clinic. 2022. Hyperglycemia in Diabetes – Symptoms and Causes. [online] Available at: https://www.mayoclinic.org/diseases-conditions/hyperglycemia/symptoms-causes/syc-20373631 [Accessed April 2022].

Logo – https://mma.prnewswire.com/media/749389/Ascensia_Diabetes_Care_Logo.jpg

SOURCE Ascensia Diabetes Care

مقالات ذات صلة

زر الذهاب إلى الأعلى